Analysis of the domestic pharmaceutical market of psychostimulants and nootropic drugs of N06BX group

Abstract

Aim. To study the nomenclature of synthetic and herbal N06BX group, presented on the pharmaceutical market ofUkraine.Results. According to the State Expert Center of the Ministry of Health of Ukraine, the pharmaceutical market of Ukraine presents 14 international non-proprietary names (INN) of drugs or 214 trade names of drugs, including forms of release registered as of the classification of ATC; December, 2019. The range of these drugs has been represented by drugs analogues, both synthetic and herbal. In total, according to the list of N06BX group, there are 29 countries producing drugs of this group.Conclusions. The market of N06BX group inUkraine has been analyzed and it has been established that drugs of domestic production occupy 52.91 %, foreign – 39.68 %, joint ventures of Ukrainian producers with foreign – 7.41 %. The main market share in the general nomenclature of the N06BX group belongs to the following manufacturers: PJSC Farmak, LLC Pharmaceutical Company Zdorovya and PJSC Pharmaceutical Firm Darnytsia. Among foreign manufacturers, the leaders are – manufacturers fromLatvia,Poland andHungary. It should be noted that pharmaceutical market ofUkraine presents 5 joint ventures with foreign countries producing drugs of N06BX group. As active substances used: citicoline, vinpocetine, piracetam, phenibut, mebicar and herbal preparations of the Ginkgo Biloba group. Release forms: solutions for injections, drops for oral use, tablets, capsules. Taking into account the lack of registered dosage forms of n-phenyl-acetyl-L-prolylglycine on the domestic market, as well as the prospects of using a nasal dosage form for transporting the active substance directly into the brain, it is advisable to conduct further research.